UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 102,595 shares of the biopharmaceutical company’s stock after purchasing an additional 6,269 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.15% of Celldex Therapeutics worth $3,487,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Novo Holdings A S purchased a new stake in shares of Celldex Therapeutics in the 2nd quarter worth $31,458,000. Point72 Asset Management L.P. grew its holdings in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after purchasing an additional 654,194 shares during the period. Marshall Wace LLP increased its position in Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock worth $50,995,000 after buying an additional 479,068 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Celldex Therapeutics by 32.0% in the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after buying an additional 321,325 shares during the period. Finally, D. E. Shaw & Co. Inc. lifted its position in shares of Celldex Therapeutics by 47.5% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock valued at $31,294,000 after buying an additional 272,389 shares in the last quarter.

Wall Street Analysts Forecast Growth

CLDX has been the subject of a number of recent analyst reports. Citigroup began coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.25.

Insiders Place Their Bets

In other Celldex Therapeutics news, CEO Anthony S. Marucci purchased 11,500 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the purchase, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock opened at $25.41 on Friday. The stock has a market capitalization of $1.69 billion, a PE ratio of -9.89 and a beta of 1.57. The business has a 50 day simple moving average of $27.38 and a 200-day simple moving average of $33.73. Celldex Therapeutics, Inc. has a 12 month low of $22.93 and a 12 month high of $53.18.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.